A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
The PBM dropped 25 more drugs from its formulary.
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
The PBM encourages step-therapy to control costs.
Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.
AstraZeneca launched a home-delivery program for breast cancer drug Arimidex through PBM Express Scripts.
Pfizer's Lipitor had not yet gone off patent before a trio of Senate healthcare heavyweights was firing off letters to the drugmaker assailing its efforts to conserve Lipitor share through a deal with pharmaceutical benefit managers.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.